Literature DB >> 2376573

Evidence that the conserved region in the steroid binding domain of the glucocorticoid receptor is required for both optimal binding of hsp90 and protection from proteolytic cleavage. A two-site model for hsp90 binding to the steroid binding domain.

P R Housley1, E R Sanchez, M Danielsen, G M Ringold, W B Pratt.   

Abstract

Steroid hormone receptors contain a conserved sequence of amino acids within the steroid binding domain, and we have previously speculated that this conserved region is the site of interaction of the glucocorticoid receptor with hsp90 (Danielsen, M., Northrop, J. P., and Ringold, G. M. (1986) EMBO J. 5, 2513-2522; Pratt, W. B., Jolly, D. J., Pratt, D. V., Hollenberg, S. M., Giguere, V., Cadepond, F. M., Schweizer-Groyer, G., Catelli, M.-G., Evans, R. M., and Baulieu, E.-E. (1988) J. Biol. Chem. 263, 267-273). In this work, we transfect COS-7 cells with three mutants of the mouse glucocorticoid receptor deleted for all or part of this conserved region. The mutant receptor missing the entire conserved region is very unstable and is found predominantly as cleavage products. Approximately one-third of the cleavage products have lost most or all of the steroid binding domain. This mutant receptor has a constitutive activity that is about one-third that of the steroid-bound wild type receptor in stimulating transcription from a reporter gene. We propose that the partial constitutive activity results from proteolytic cleavage of the steroid binding domain from the rest of the receptor, thus removing the functional repression determined by this domain. This mutant receptor is associated with hsp90 in cytosols prepared in the presence of molybdate but, when molybdate is not present, the receptor is unstable and there is very little receptor-associated hsp90. This observation is consistent with the proposal that binding of hsp90 helps to stabilize the glucocorticoid receptor against proteolysis, and it demonstrates that the site of molybdate interaction with the receptor lies outside of the conserved sequence. Our data are interpreted according to a two-site model in which hsp90 interacts with the steroid binding domain at two sites. One site is in the conserved sequence, and the other is at a transition metal oxyanion binding site, located between the conserved sequence and the COOH terminus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2376573

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Aldosterone antagonists destabilize the mineralocorticosteroid receptor.

Authors:  B Couette; M Lombes; E E Baulieu; M E Rafestin-Oblin
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

2.  Androgen receptor gene mutations in human prostate cancer.

Authors:  J R Newmark; D O Hardy; D C Tonb; B S Carter; J I Epstein; W B Isaacs; T R Brown; E R Barrack
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

3.  Polymorphisms of the glucocorticoid receptor gene in laboratory and wild rats: steroid binding properties of trinucleotide CAG repeat length variants.

Authors:  R P Heeley; E Gill; B van Zutphen; C J Kenyon; R G Sutcliffe
Journal:  Mamm Genome       Date:  1998-03       Impact factor: 2.957

4.  Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains.

Authors:  Mudit Kakar; Charu Kanwal; J Rian Davis; Henan Li; Carol S Lim
Journal:  AAPS J       Date:  2006-11-22       Impact factor: 4.009

5.  Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activity.

Authors:  Irene M Wolf; Sumudra Periyasamy; Terry Hinds; Weidong Yong; Weinian Shou; Edwin R Sanchez
Journal:  J Steroid Biochem Mol Biol       Date:  2008-11-27       Impact factor: 4.292

6.  Conformational activation of a basic helix-loop-helix protein (MyoD1) by the C-terminal region of murine HSP90 (HSP84).

Authors:  R Shaknovich; G Shue; D S Kohtz
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.